Genes & Nutrition

, Volume 7, Issue 1, pp 3–9 | Cite as

Tocotrienols and breast cancer: the evidence to date

  • Kalanithi Nesaretnam
  • Puvaneswari Meganathan
  • Sheela Devi Veerasenan
  • Kanga Rani Selvaduray
Review

Abstract

Breast cancer is the second most frequent cancer affecting women worldwide after lung cancer. The toxicity factor associated with synthetic drugs has turned the attention toward natural compounds as the primary focus of interest as anticancer agents. Vitamin E derivatives consisting of the well-established tocopherols and their analogs namely tocotrienols have been extensively studied due to their remarkable biological properties. While tocopherols have failed to offer protection, tocotrienols, in particular, α-, δ-, and γ-tocotrienols alone and in combination have demonstrated anticancer properties. The discovery of the antiangiogenic, antiproliferative, and apoptotic effects of tocotrienols, as well as their role as an inducer of immunological functions, not only reveals a new horizon as a potent antitumor agent but also reinforces the notion that tocotrienols are indeed more than antioxidants. On the basis of a transcriptomic platform, we have recently demonstrated a novel mechanism for tocotrienol activity that involves estrogen receptor (ER) signaling. In silico simulations and in vitro binding analyses indicate a high affinity of specific forms of tocotrienols for ERβ, but not for ERα. Moreover, we have demonstrated that specific tocotrienols increase ERβ translocation into the nucleus which, in turn, activates the expression of estrogen-responsive genes (MIC-1, EGR-1 and Cathepsin D) in breast cancer cells only expressing ERβ cells (MDA-MB-231) and in cells expressing both ER isoforms (MCF-7). The binding of specific tocotrienol forms to ERβ is associated with the alteration of cell morphology, caspase-3 activation, DNA fragmentation, and apoptosis. Furthermore, a recently concluded clinical trial seems to suggest that tocotrienols in combination with tamoxifen may have the potential to extend breast cancer-specific survival.

Keywords

Tocotrienols Anticancer Antiproliferative Tamoxifen Apoptosis Chemopreventive 

References

  1. Abdul Hafid SR, Radhakrishnan AK, Nesaretnam K (2010) Tocotrienols are good adjuvants for developing cancer vaccines. Cancer 10 (Article in press)Google Scholar
  2. Balfe P, McCann A, McGoldrick A, McAllister K, Kennedy M, Dervan P, Kerin MJ (2004) Estrogen receptor α and β profiling in human breast cancer. J Cancer Surg 30:469–474Google Scholar
  3. Behery FA, Elnagar AY, Akl MR, Wali VB, Abuasal B, Kaddoumi A, Sylvester PW, El Sayed KA (2010) Redox-silent tocotrienol esters as breast cancer proliferation and migration inhibitors. Bioorg Med Chem 18:8066–8075PubMedCrossRefGoogle Scholar
  4. Biswas DK, Cruz A, Pettit N, Mutter GL, Pardee AB (2001) A therapeutic target for hormone-independent estrogen receptor-positive breast cancers. Mol Med 7:59–67PubMedGoogle Scholar
  5. Cancer.Org (2010) Cancer Facts and Figures 2010. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf. Accessed 10 Dec 2010
  6. Charts Bin (2010) Current Worldwide Breast Cancer Incidence Rate. http://chartsbin.com/view/yq6. Accessed 8 Dec 2010
  7. Comitato R, Nesaretnam K, Leoni G, Ambra R, Canali R, Bolli A, Marino M, Virgili F (2009) A novel mechanism of natural vitamin E tocotrienol activity: involvement of ERβ signal transduction. Am J Physiol Endocrinol Metab 297:E427–E437PubMedCrossRefGoogle Scholar
  8. Comitato R, Leoni G, Canali R, Ambra R, Nesaretnam K, Virgili F (2010) Tocotrienols activity in MCF-7 breast cancer cells: involvement of ERβ signal transduction. Mol Nutr Food Res 54(5):669–678PubMedCrossRefGoogle Scholar
  9. Cullen R, Maguire TM, McDermott EW, Hill ADK, O’Higgins NJO, Duffy MJ (2001) Studies on oestrogen receptor-α and–β mRNA in breast cancer. Eur J Cancer 37:1118–1122PubMedCrossRefGoogle Scholar
  10. Dayton S, Hashimoto S, Wollman J (1977) Effect of high oleic and high linoleic safflower oils on mammary tumors induced in rats by 7, 12-Dimethylbenzanthracene. J Nutr 107:1353–1360PubMedGoogle Scholar
  11. Fog C, Christensen I, Lykkesgeldt A (2005) Characterization of human breast cancer cell line, MCF-7/RU58R-1, resistant to the pure antiestrogen RU 58, 668. Breast Cancer Res Tr 91:133–144CrossRefGoogle Scholar
  12. Guthrie N, Gapor A, Chambers AF, Carroll KK (1997) Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination. J Nutr 127:544S–548SPubMedGoogle Scholar
  13. Healy SJM, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A (2009) Targetting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol 625:234–246PubMedCrossRefGoogle Scholar
  14. Ingram DM, Nottager E, Roberts T (1991) The role of diet in the development of breast cancer: a case control study of patients with breast cancer. Br J Cancer 64:187–191PubMedCrossRefGoogle Scholar
  15. Leonessa F, Jacobson M, Boyle B, Lippman J, McGarvey M, Clarke R (1994) Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: Isobologram, Drug accumulation, and Mr 170, 000 glycoprotein (gp170) binding studies. Cancer Res 54:441–447PubMedGoogle Scholar
  16. McIntyre BS, Briski KP, Gapor A, Sylvester PW (2000) Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Lipids 35:171–180PubMedCrossRefGoogle Scholar
  17. Mo H, Elson CE (1999) Apoptosis and cell-cycle arrest in human and murine tumors cells are initiated by isoprenoids. J Nutr 129(4):804–813PubMedGoogle Scholar
  18. National Cancer Institute (2010) Surveillance epidemiology and end results. http://seer.cancer.gov/statfacts/html/breast.html. Accessed 8 Dec 2010
  19. National Cancer Institute (2010) Tamoxifen. http://www.cancer.gov/cancertopics/factsheet/Therapy/tamoxifen. Accessed 8 Dec 2010
  20. Nesaretnam K (2008) Multitargeted therapy of cancer by tocotrienols. Cancer Lett 269:388–395PubMedCrossRefGoogle Scholar
  21. Nesaretnam K, Guthrie N, Chambers AF, Carroll KK (1992) Effect of tocotrienols on the growth of a human breast cancer cell line in culture. Lipids 30:1139–1145CrossRefGoogle Scholar
  22. Nesaretnam K, Guthrie N, Chambers AF, Caroll KK (1995) Effect of tocotrienols on the growth of a human breast cancer cell line in culture. Lipids 30:1139–1143PubMedCrossRefGoogle Scholar
  23. Nesaretnam K, Stephen R, Dils R, Darbre P (1998) Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status. Lipids 33:461–469PubMedCrossRefGoogle Scholar
  24. Nesaretnam K, Dorasamy S, Darbre PD (2000) Tocotrienols inhibit growth of ZR-75-1 breast cancer cells. Int J Food Sci Nutr 51:S95–S103PubMedCrossRefGoogle Scholar
  25. Nesaretnam K, Ambra R, Selvaduray KR, Radhakrishnan A, Canali R, Virgili F (2004a) Tocotrienol-rich fraction from palm oil and gene expression in human breast cancer cells. Ann N Y Acad Sci 1031:143–157PubMedCrossRefGoogle Scholar
  26. Nesaretnam K, Ambra R, Selvaduray KR, Radhakrishnan A, Reimann K, Razak G, Virgili F (2004b) Tocotrienol-rich fraction from palm oil affects gene expression in tumors resulting from MCF-7 cell inoculation in athymic mice. Lipids 39:459–467PubMedCrossRefGoogle Scholar
  27. Nesaretnam K, Yew WW, Wahid MB (2007a) Tocotrienols and cancer: beyond antioxidant activity. Eur J Lipi Sci Technol 109:445–452CrossRefGoogle Scholar
  28. Nesaretnam K, Gomez PA, Selvaduray KR, Abdul Razak G (2007b) Tocotrienol levels in adipose tissue of benign and malignant breast lumps in patients in Malaysia. Asia Pac J Clin Nutr 16(3):498–504PubMedGoogle Scholar
  29. Nesaretnam K, Selvaduray KR, Abdul Razak G, Veerasenan SD, Gomez PA (2010) Effectiveness of tocotrienol-rich fraction combine with tamoxifen in the management of women with early breast cancer: a pilot clinical trial. Breast Cancer Res (Article in press)Google Scholar
  30. Okabe M, Oji M, Ikeda I, Tachibana H (2002) Yamada K: tocotrienol level in various tissues of Sprague-Dawley rats after intragastric administration of tocotrienols. Biosci Biotechnol Biochem 66:1768–1771PubMedCrossRefGoogle Scholar
  31. Breast Cancer.Org (2010) Breast cancer statistics. http://www.breastcancer.org/symptoms/understand_bc/statistics.jsp?gclid=COzU2ZDJ5KUCFUV76wodGCGL0Q. Accessed 8 Dec 2010
  32. Park SK, Sanders BG, Kline K (2010) Tocotrienols induce apoptosis in breast cancer cell lines via an endoplasmic reticulum stress-dependant increase in extrinsic death receptor signalling. Breast Cancer Res Treat 124(2):361–375PubMedCrossRefGoogle Scholar
  33. Pierpaoli E, Viola V, Pilolli F, Piroddi M, Galli F, Provincialli M (2010) γ- and δ- tocotrienols exert a more potent anticancer effect than alpha-tocopheryl succinate on breast cancer cell lines irrespective of HER-2/neu expression. Life Sci 86:668–675PubMedCrossRefGoogle Scholar
  34. Platet N, Cathiard AM, Gleizes M, Garcia M (2004) Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51:55–67PubMedCrossRefGoogle Scholar
  35. Selvaduray KR, Radhakrishnan A, Kutty MK, Nesaretnam K (2010) Palm tocotrienols inhibit proliferation of murine mammary cancer cells and induce expression of interleukin-24 mRNA. J Interferon Cytokine Res 30(12):909–916PubMedCrossRefGoogle Scholar
  36. Sen CK, Khanna S, Roy S (2006) Tocotrienols: vitamin E beyond tocopherols. Life Sci 78(18):2088–2098PubMedCrossRefGoogle Scholar
  37. Shafiq N, Malhotra S, Pandhi P, Nada R (2005) Comparative gastrointestinal toxicity of selective cyclooxygenase (COX-2) inhibitors. Indian J Exp Biol 43:614–619PubMedGoogle Scholar
  38. Shah S, Sylvester PW (2004) Tocotrienol-induced caspase-8 activation is unrelated to death receptor apoptotic signaling in neoplastic mammary epithelial cells. Exp Biol Med (Maywood) 229:745–755Google Scholar
  39. Shirode AB, Sylvester PW (2010) Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkB signaling. Biomed Pharmacother 64:327–332PubMedCrossRefGoogle Scholar
  40. Skliris GP, Leygue E, Watson PH, Murphy LC (2008) Estrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Bio 109:1–10CrossRefGoogle Scholar
  41. Sundram K, Khor HT, Ong ASH, Pathmanathan R (1989) Effect of dietary palm oils in mammary carcinogenesis in female rats induced by 7, 12-Dimethylbenz(α)anthracene. Cancer Res 49:1447–1451PubMedGoogle Scholar
  42. Sylvester PW, Shah SJ (2005) Mechanisms mediating the antiproliferative and apoptotic effects of vitamin E in mammary cancer cells. Front Biosci 10:109–699CrossRefGoogle Scholar
  43. Sylvester PW, Russell M, Ip MM, Ip C (1986) Comparative effects of different animal and vegetable fats before and during carcinogenesis administration on mammary tumorigenesis, sexual maturation and endocrine function in rats. Cancer Res 46:757–762PubMedGoogle Scholar
  44. Theriault A, Chao J-T, Wqang Q, Gapor A, Adeli K (1999) Tocotrienol: a review of its therapeutic potential. Clin Biochem 32(5):309–319PubMedCrossRefGoogle Scholar
  45. Wali VB, Sylvester PW (2007) Synergistic antiproliferative effects of c-tocotrienol and statin treatment on mammary tumor cells. Lipids 42:1113–1123PubMedCrossRefGoogle Scholar
  46. Wali VB, Bachawal SV, Sylvester PW (2009a) Suppression in Mevalonate synthesis mediates antitumor effects of combined statin and γ–tocotrienol treatment. Lipids 44:925–934PubMedCrossRefGoogle Scholar
  47. Wali VB, Bachawal SV, Sylvester PW (2009b) Combine treatment of gamma tocotrienol with statins induce mammary tumor cell cycle arrest in G1. Exp Biol Med (Maywood) 234:639–650CrossRefGoogle Scholar
  48. Wali VB, Bachawal SV, Sylvester PW (2009c) Endoplasmic reticulum stress mediates c-tocotrienol and apoptosis in mammary tumor cells. Apoptosis 14:1366–1377PubMedCrossRefGoogle Scholar
  49. Yap WN, Zaiden N, Tan YL, Ngoh CP, Zhang XW, Wong YC, Yap YL (2010) Id1, inhibitor of differentiation, is a key protein mediating anti-tumor responses of gamma-tocotrienol in breast cancer cells. Cancer Lett 291:187–199PubMedCrossRefGoogle Scholar
  50. Yde CW, Clausen MP, Bennetzen MV, Lykkesfeldt AE, Mouritsen OG, Guerra B (2009) The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells. Anti-Cancer Drugs 20(8):723–735PubMedCrossRefGoogle Scholar
  51. Yoshida Y, Niki E, Noguchi N (2003) Comparative study on the action of tocopherols and tocotrienols as antioxidant: chemical and physical effects. Chem Phys Lipids 123(1):63–75PubMedCrossRefGoogle Scholar
  52. Yu W, Simmons-Menchaca M, Gapor A, Sanders BG, Kline K (1999) Induction of apoptosis in human breast cancer cells by tocopherols and tocotrienols. Nutr Cancer 33(1):26–32PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Kalanithi Nesaretnam
    • 1
  • Puvaneswari Meganathan
    • 1
  • Sheela Devi Veerasenan
    • 1
  • Kanga Rani Selvaduray
    • 1
  1. 1.Product Development and Advisory Services DivisionMalaysian Palm Oil BoardKajang, SelangorMalaysia

Personalised recommendations